Recently, a patient with an immunodeficiency was admitted in our hospital with fever, pain and a large abscess in the pelvic region, after an incomplete treatment of prostatitis with ciprofloxacin, for which no causal agent was not sought. For several weeks, he was treated with different beta-lactam antibiotics and vancomycin, however only a partial clinical response was achieved. On the other hand, the development of de novo abscess formation in the lumbar region, and the development of cutaneous ulcers and abscesses were seen. Finally, after several weeks of treatment, in a cutaneous biopsy Mycoplasma hominis was identified with the 16S rRNA gene sequencing [1] .
In contrast, clear cut extra-urogenital infections by M. hominis, such as arthritis, central nervous disease, endocarditis, prosthetic joint and bone infections, and soft tissue infections are reported and in some cases these infections may be fatal [1, [10] [11] [12] . Probably, these infections arise as a consequence in the breach of genitourinary mucosa, followed by haematogenous spread to the different organs and tissues [4, 13] . The main reasons these bacteria are able to cause disseminated infections, may be the immune status of the patient, the use of beta-lactams antibiotics in first line treatment of soft tissue infections, the lack of sensitive diagnostic assays, and often the low awareness of the potential invasiveness of M. hominis among clinicians. Therefore, the diagnosis is usually made only after several days or even weeks, or by coincidence if molecular assays or sequencing techniques are performed on normal sterile body sites [1, 11, 12] . However, these publications show the potential of M. hominis to cause invasive and disseminated infections. Immunosuppression, and hypogammaglobulinemia in particular, seems to be associated with disseminated extra-genitourinary M. hominis infections, and was seen in half of the patients [12, 13] . In our patient hypogammaglobulinemia was induced by rituximab, a CD20 monoclonal antibody, which targets malignant CD20 expressing B cells in patients with non-Hodgkin lymphoma.
Diagnostic options for the diagnosis of M. hominis infections are limited. These bacteria do not possess a cell wall, and therefore they cannot be visualized in a Gram stain in clinical samples. Furthermore, M. hominis is a fastidious organism and a prolonged incubation of genitourinary cultures is necessary to produce visible growth, cultures are often overgrown by commensal flora, and specific Mycoplasma/ Ureaplasma culture is usually not performed in a routine laboratory. Molecular assays for these microorganisms are so far not widely spread in routine laboratories. Nevertheless, we believe that in the case of severe (extra) genitourinary infections, a broad screening for possible causative organisms in addition to C. trachomatis and N. gonorrhoeae is a reasonable policy. In our laboratory, an in house Taqman® Array Card is used for the simultaneous detection of 13 microorganisms, C. trachomatis, N. gonorrhoeae, Trichomonas vaginalis, M. hominis and M. genitalium, Ureaplasma urealyticum and U. parvum, Treponema pallidum, Herpes Simplex virus type 1 and 2, Cytomegalovirus, Adenovirus, and Haemophilus ducreyi. Only when significant high concentrations of M. hominis are found in genitourinary and deep seated samples, clinicians receive antibiotic advice on the lab report so they can decide whether the present symptoms can eventually be explained by M. hominis. In many commercial molecular assays for STI screening, the separate detection of M. hominis DNA is not included. On extra-genital samples often a broad-range bacterial PCR which uses a primer pair aimed at highly conserved DNA coding regions of bacterial rRNA is performed when culture stays negative [11] . Susceptibility testing of Mycoplasma isolates in a routine bacteriology laboratory is also challenging, and for genitourinary infection is usually not performed. Despite numerous publications, there have been no universally accepted or standardized broth dilutionor agar-based methods designating the optimum testing conditions, pH, media, and duration of incubation. The lack of a consensus method for disk susceptibility testing or MIC determination with antibiotic gradient strips or micro dilution has resulted in considerable confusion regarding the antimicrobial activities of various drugs against these organisms [14] . Understandably, at this moment there are no CLSI or EUCAST breakpoints available. Currently, commercial kits for the combined identification and susceptibility testing in liquid media are used in routine laboratory, in which the presence of M. hominis in genitourinary samples is detected by biochemical tests, simultaneously with susceptibility testing [15, 16] . These kits are easy to use, the results are available after one day of incubation, and are often applied in studies to determine activities of antibiotics. In Table 1 the summary of susceptibility testing of M. hominis and U. urealyticum isolates from genitourinary samples in recent studies is shown [17] [18] [19] [20] [21] [22] [23] [24] . These results shown a diversity in resistance rates of these isolates against different antibiotic classes. The isolates are from mostly pregnant women, asymptomatic patients, and patients with genitourinary complaints. The activity of some antibiotics is further compromised if the cumulative resistance of M. hominis and U. urealyticum, against the antibiotics was reported [16, 17, 25] . Doxycycline remains one of the most active antibiotics; however, in some studies resistance up to 36% was reported. Resistance against tetracyclines was significantly different (1.8-95%), dependent of the country and continent [18] . A reason may be that M. hominis is transferred through sexual intercourse, and this might promote the spread of resistant clones [18] . On the other hand, moxifloxacin is very active against M. hominis and other genital Mycoplasma and Ureaplasma species, and very low MIC 90 values were reported [26] . M. hominis resistance against moxifloxacin so far is rare, but has recently been reported [12] . M. hominis is resistant to 14-and 15-membered macrolides, including erythromycin, azithromycin, and clarithromycin, due to a mutation in domain V of 23S rRNA, mutations in ribosomal protein L4 gene and antibiotic efflux as well [27] . Macrolides are not active against M. hominis in contrast to M. genitalium, and other Mycoplasma species, except for josamycin, a newer macrolide formulation; however, this antibiotic may not be available in some countries like Belgium. Clindamycin is the most active agent against M. hominis [28, 29] . Furthermore, tigecycline, has shown to be very active (MIC 50 /MIC 90 , 0.25/0.5 mg/ml; range, 0.125 mg/ml-0.5 mg/ml), while linezolid shows only a modest activity against M. hominis (MIC 90 8 mg/ml, range 2-8 mg/ml) [1] . Beta-lactam and glycopeptide antibiotics are not effective in the treatment of M. hominis, due to the lack of a bacterial cell wall and thus peptidoglycan, the main action site of beta-lactams and glycopeptides. Therefore, antibiotics from other classes are the first choice.
The treatment of patients with severe genitourinary infections is different from the treatment of patient with extra-genitourinary tract infections. In the first, a common empiric antibiotic is used against the most probable pathogenic species, namely C. trachomatis, N. gonorrhoeae, M. genitalium, Enterobacteriaceae, and anaerobic bacteria. Centers for Disease Control and Prevention recommend a regimen containing doxycycline [2] . However, tetracyclines and quinolones are no options in pregnant women, therefore josamycin or clindamycin would be reasonable alternatives; the role of linezolid needs to be further examined [18] . In extra-urogenital infections by M. hominis, doxycycline is also recommended, sometimes in association with surgery, dependent of the infection site [2, 11] . With our patient, the clinical response to moxifloxacin was only partial, and the patient recovered quickly after clindamycin therapy was started, but he was further treated as an outpatient for several weeks. The duration of the treatment is, due to individual case reports only, dependent on clinical judgement, and should continue until clinical signs of infection have completely resolved [2] . Microbiologists and infectious disease specialist should be aware, that these low virulence micro-organisms, may be resistant to the common used antimicrobials [12, 18] . Therefore, in case of infections caused by non-cultivable micro-organisms, such as M. hominis, it is advised that some kind of susceptibility assay is performed, as a result of significant geographical and age related differences in the susceptibility between isolates [10, 18] . Some molecular assays for the detection of mutation resistance markers at molecular level, which might be responsible for therapy failure, such Volume 2 • Issue 2 • 1000114 J Antimicro ISSN: 2472-1212, Antimicro an open access journal as with tetracycline, and quinolones resistance already exist, however these techniques are mostly used for research purposes [10] .
In conclusion, in many studies the role of M. hominis in genitourinary infections so far has not been clear. Nevertheless, there are some reports, suggestive of a causal pathophysiologic impact of this bacterium in the lower and upper genital tract. Additionally M. hominis infection is probably an important cause of male infertility, and publications of severe invasive infections by M. hominis show that this bacterium should not just be underestimated as an innocent by stander.
